Your browser doesn't support javascript.
loading
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
Fairhurst, Robin A; Furet, Pascal; Imbach-Weese, Patricia; Stauffer, Frédéric; Rueeger, Heinrich; McCarthy, Clive; Ripoche, Sebastien; Oswald, Susanne; Arnaud, Bertrand; Jary, Aline; Maira, Michel; Schnell, Christian; Guthy, Daniel A; Wartmann, Markus; Kiffe, Michael; Desrayaud, Sandrine; Blasco, Francesca; Widmer, Toni; Seiler, Frank; Gutmann, Sascha; Knapp, Mark; Caravatti, Giorgio.
Afiliación
  • Fairhurst RA; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Furet P; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Imbach-Weese P; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Stauffer F; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Rueeger H; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • McCarthy C; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Ripoche S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Oswald S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Arnaud B; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Jary A; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Maira M; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Schnell C; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Guthy DA; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Wartmann M; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Kiffe M; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Desrayaud S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Blasco F; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Widmer T; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Seiler F; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Gutmann S; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
  • Knapp M; Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.
  • Caravatti G; Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
J Med Chem ; 65(12): 8345-8379, 2022 06 23.
Article en En | MEDLINE | ID: mdl-35500094
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositol 3-Quinasas / Antineoplásicos Tipo de estudio: Diagnostic_studies Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositol 3-Quinasas / Antineoplásicos Tipo de estudio: Diagnostic_studies Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos